Electronic Patient Record System. Data were collected from 2.

Methods

outcomes locally can provide data regarding possible additional ben-
congenital anomalies. Published data is reassuring but awareness of
the offspring, issues concerning drug safety, mode of delivery and
reproductive years. Concerns regarding family planning are the
impact of CD on fertility and course of pregnancy, transmission to
the offspring, issues concerning drug safety, mode of delivery and
congenital anomalies. Published data is reassuring but awareness of
outcomes locally can provide data regarding possible additional ben-
efit from specialist obstetric medicine service.

Methods

Pregnant patients with CD were identified through the
Electronic Patient Record System. Data were collected from
October 2008–November 2012. Further information on outcomes
was gathered from individual consultation with patients.

Results

80 pregnancies in 57 patients with CD were identified. 10
patients currently pregnant, 9 patients (13 pregnancies) with
incomplete data were excluded. Therefore, pregnancy outcomes of
57 pregnancies/38 patients (mean age: 30.7 years) were analysed.
31/38 (82%) of patients had luminal disease, 7/38 (18%) perianal
disease, 36/38 (95%) conceived naturally, 1/38 (2.5%) by assisted
delivery, 1/38 (2.5%) by IVF/ET. The mean birth weight of newborns
was 3 kg (1.9 kg–5.1 kg), 4/38 (11%) of the babies were of low BW (<2.5 kg).
Neonatal issues were recorded in 5/46 (11%); 1 diabetes mellitus, 2
neonatal deaths occurred in the 1st trimester, 4/15 (27%) in the 2nd,
1/15 (7%) in the 3rd. Of all pregnancies with flares, 9/15 (60%) were on no CD therapy.
No treatment in early pregnancy, 4/46 (5%) on biologics + t
biопurines (TPN), 6/46 (10%) on TPN, 6/46 (10%) on TPN + 5-ASA,
7/46 (12%) on 5-ASA, 2/46 (5%) on steroids and 1/46 (2%) on
elemental diet. 15/46 (26%) pregnancies had flares, of which
4/46 (9%) were due to use of medications unrelated to CD that could potentially cause congenital
anomalies.

Conclusion

The number of pregnancies in a specialist IBD clinic is
high up to 20/year in this series highlighting a potential additional
service need. A specialist obstetric medicine service can provide reassurance regarding safety of drugs in pregnancy, which in turn may reduce flare rates and result in good pregnancy outcomes. Observed outcomes did not fall outside that expected from larger reported series.

Disclosure of Interest

None Declared

REFERENCES

approx. £119,000 for investigations and consultations. Using a Calprotectin® (Preventis, GmbH) point of contact FC test, it was estimated that a saving of £89,000 could be achieved. A pathway for investigating chronic diarrhoea using Calprotectin® was designed and implemented in the community (population 150,000) between September 2011-March 2012. This pathway was validated using manufacturer cut-offs of <15μg/g, 15–60μg/g and >60μg/g. Patients with FC results of 15–60 and >60 were deemed to have an inflammatory process (p < 0.005). Age, comorbidities, previous duration of remission, disease extent, smoking, trial medication adherence and baseline FC (cut-off at 150μg/kg stool or as a continuous variable) did not remain in the final model.

Conclusion In this study, sigmoidoscopy appearance at baseline was the sole factor predicting relapse over 1 year of maintenance mesalazine 2.4g, whereas calprotectin level was not a predictor, perhaps because of wide variability in this group of patients. FC may have more value in measuring relative change in individual patients.

Disclosure of Interest A. Hawthorne Grant/Research Support from: CODA study supported by unrestricted grant from Warner Chilcott, D. Gillespie: None Declared, C. Probert: None Declared

Introduction Faecal calprotectin (FC) has become a useful marker of mucosal healing, with studies showing raised levels predictive of relapse.1,2,3 These studies did not assess mucosal healing however, so did not compare calprotectin with mucosal appearance as predictors of relapse.

Methods In the CODA (Colitis Once Daily Asacol®) trial of once daily (OD) Asacol® (three 800mg tablets) vs one 800mg tablet taken three times daily (TDS), 213 UC patients in remission for >4 years, but relapse in the past 2 years, were recruited. Baseline FC (Phical ELISA kit) was collected and rectal sigmoidoscopy (sig) score at baseline, and relapse or 1 year (using the modified Baron score: 0 = normal; 1 = erythema, decreased vascular pattern; 2 = marked erythema, absent vascular pattern, friability, erosions; 3 = spontaneous bleeding, ulceration). At entry patients had no symptoms of active disease, with a sig score of 0 or 1. Follow-up was for 1 year or until relapse (symptoms of active disease with a sig score of 2 or 3). Demographic factors, concomitant drugs, FC, sig score, CRP, and adherence were evaluated in a Cox regression model of time to relapse. Remission duration prior to entry was 6.0 (3–12) months. Disease extent was extensive (50.0%), Lt. sided (54.9%), proctitis (15.6%). At entry FC was 78mg/kg stool (23.3–159.4), sigmoidoscopy score 0 (70.9%), 1 (29.1%). All were taking mesalazine, and 11.7% thiopurines. Baseline FC was higher if sig score was 1 (109[38–335]) than if 0 (62[21–120], p = 0.001, but did not differ according to disease extent or medication (including aspirin (n = 18) and occasional NSAIDs (n = 6). Remission rates at one year were 62% overall (68.9% in OD and 55.5% in TDS group). Factors associated with time to relapse were explored in a Cox proportional hazards model, with baseline FC dichotomised at 150μg/kg stool (as by Costa et al. Relapse risk was 2.5 times higher in those with baseline sig score 1 compared to score 0 (95% CI 1.32–4.76, p = 0.005). Age, comorbidities, previous duration of remission, disease extent, smoking, trial medication adherence and baseline FC (cut-off at 150μg/kg stool or as a continuous variable) did not remain in the final model.

Conclusion In this study, sigmoidoscopy appearance at baseline was the sole factor predicting relapse over 1 year of maintenance mesalazine 2.4g, whereas calprotectin level was not a predictor, perhaps because of wide variability in this group of patients. FC may have more value in measuring relative change in individual patients.

Disclosure of Interest A. Hawthorne Grant/Research Support from: CODA study supported by unrestricted grant from Warner Chilcott, D. Gillespie: None Declared, C. Probert: None Declared

REFERENCES

PTU-058 ONE YEAR LIKELIHOOD OF RELAPSE IN ULCERATIVE COLITIS (UC) IS PREDICTED BY MUCOSAL APPEARANCE BUT NOT BY FAECAL CALPROTECTIN: DATA FROM THE CODA STUDY OF ONCE DAILY VERSUS THREE TIMES DAILY ASACOL

doi:10.1136/gutjnl-2013-304907.150

A B Hawthorne, D Gillespie, C Probert. Medicine, University Hospital of UK; SE UK Trials Unit, Cardiff; Institute of translational medicine, Liverpool University, Liverpool, UK

Introduction Faecal calprotectin (FC) has become a useful marker of mucosal healing, with studies showing raised levels predictive of relapse.1,2,3 These studies did not assess mucosal healing however, so did not compare calprotectin with mucosal appearance as predictors of relapse.

Methods In the CODA (Colitis Once Daily Asacol®) trial of once daily (OD) Asacol® (three 800mg tablets) vs one 800mg tablet taken three times daily (TDS), 213 UC patients in remission for >4 years, but relapse in the past 2 years, were recruited. Baseline FC (Phical ELISA kit) was collected and rectal sigmoidoscopy (sig) score at baseline, and relapse or 1 year (using the modified Baron score: 0 = normal; 1 = erythema, decreased vascular pattern; 2 = marked erythema, absent vascular pattern, friability, erosions; 3 = spontaneous bleeding, ulceration). At entry patients had no symptoms of active disease, with a sig score of 0 or 1. Follow-up was for 1 year or until relapse (symptoms of active disease with a sig score of 2 or 3). Demographic factors, concomitant drugs, FC, sig score, CRP, and adherence were evaluated in a Cox regression model of time to relapse.

Results (Shown as median[IQR] unless stated otherwise). Remission duration prior to entry was 6.0 (3–12) months. Disease extent was extensive (50.0%), Lt. sided (54.9%), proctitis (15.6%). At entry FC was 78mg/kg stool (23.3–159.4), sigmoidoscopy score 0 (70.9%), 1 (29.1%). All were taking mesalazine, and 11.7% thiopurines. Baseline FC was higher if sig score was 1 (109[38–335]) than if 0 (62[21–120], p = 0.001, but did not differ according to disease extent or medication (including aspirin (n = 18) and occasional NSAIDs (n = 6). Remission rates at one year were 62% overall (68.9% in OD and 55.5% in TDS group). Factors associated with time to relapse were explored in a Cox proportional hazards model, with baseline FC dichotomised at 150μg/kg stool (as by Costa et al. Relapse risk was 2.5 times higher in those with baseline sig score 1 compared to score 0 (95% CI 1.32–4.76, p = 0.005). Age, comorbidities, previous duration of remission, disease extent, smoking, trial medication adherence and baseline FC (cut-off at 150μg/kg stool or as a continuous variable) did not remain in the final model.

Conclusion In this study, sigmoidoscopy appearance at baseline was the sole factor predicting relapse over 1 year of maintenance mesalazine 2.4g, whereas calprotectin level was not a predictor, perhaps because of wide variability in this group of patients. FC may have more value in measuring relative change in individual patients.

Disclosure of Interest A. Hawthorne Grant/Research Support from: CODA study supported by unrestricted grant from Warner Chilcott, D. Gillespie: None Declared, C. Probert: None Declared

PTU-059 ADALIMUMAB THERAPY REDUCES HOSPITALIZATION AND COLECTOMY RATES IN PATIENTS WITH ULCERATIVE COLITIS AMONG INITIAL RESPONDERS

doi:10.1136/gutjnl-2013-304907.151

B G Feagan, W J Sandborn, M Skup, M Yang, A Lazar, R B Thakkar, U Choo, P M Mulani. Robarts Research Institute, University of Western Ontario, London, ON, Canada; UESCO, La Jolla, CA; AbbVie, Abbott Park, IL, United States; AbbVie Deutschland, Ludwigshafen, Germany

Introduction Two double-blind, placebo-controlled trials (ULTRA 1 and 2) revealed that adalimumab (ADA) therapy significantly reduces hospitalisation and non-significantly decreases colectomy rates in patients with moderate to severe ulcerative colitis (UC).1

Methods We assessed the effect of an ADA 160/80/40 mg treatment regimen on risk reduction of all-cause and UC-related hospitalisation and colectomy in these 2 trials among initial ADA responders. The pooled dataset included 963 patients (480 ADA, 483 placebo [PBO]). Hospitalization and colectomy events were based on safety reports reviewed by 2 gastroenterologists who were blinded to treatment. Conservatively, hospitalizations from initial ADA non-responders (per Mayo score at Week 8) through Week 8 were counted, but were censored after Week 8 to reflect the clinical practise pattern of continuing treatment in initial ADA responders. Risk and number of hospitalizations were compared between groups using person-year (PY)–based incidence rates (IRs) and Poisson regression, respectively; Z-scores were used to assess statistical differences.2

Results 35% and 34% reductions in the number of patients hospitalised and number of hospitalizations for any reason, respectively, were observed with ADA therapy vs. PBO (table, P < 0.05 for both comparisons). When UC-related hospitalizations were compared, reductions for rate (50%) and number (54%) of hospitalizations were both statistically significant, too.

Conclusion Initial ADA-responders had a significantly lower risk for UC-related and all-cause hospitalisation compared with PBO. Reduction of all-cause hospitalisation is unique for ADA compared with any other anti–tumour necrosis factor agent. A non-significantly lower colectomy rate in patients receiving ADA vs. those receiving PBO was also observed.